Blog

Immunogenicity to biologic therapies is, by definition, a biomarker, a measurable biological response to therapeutic exposure. However, industry practice often treats immunogenicity as a uniquely separate scientific area, relying on a standardized three-tier testing paradigm applied broadly across programs, regardless of the context of use.  This one-size-fits-all approach arose from a reasonable desire to prevent…